ArticleNature2018
A homing system targets therapeutic T cells to brain cancer.
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Deciphering T Cell Dynamics in Alzheimer's Disease Pathogenesis: Insights and Implications.Current neuropharmacology · 2025Review
- Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders.Nature biomedical engineering · 2024Article
- Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.Scientific reports · 2024Article
- c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.Bioengineered · 2022Article
- A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity.Oncoimmunology · 2022Article
- Article
- Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment.Nature communications · 2021Article
- Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.Neuro-oncology · 2021Article
- A novel molecular magnetic resonance imaging agent targeting activated leukocyte cell adhesion molecule as demonstrated in mouse brain metastasis models.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment.Frontiers in pharmacology · 2021Review
- Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020Observational
- Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma.Frontiers in oncology · 2020Review
- Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- Effective effectors: How T cells access and infiltrate the central nervous system.Pharmacology & therapeutics · 2019Review
- Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166.Clinical & experimental metastasis · 2019Review
- A sequence conserved between CD5 and CD6 binds an FERM domain and exerts a restraint on T-cell activation.Immunology · 2019Article
- Addition of the C-terminus of CD6 to a chimeric antigen receptor enhances cytotoxicity and does not compromise expression.Immunology · 2019Article
- Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers.Frontiers in oncology · 2019Review
- Site-Specific DC Surface Signatures Influence CD4Frontiers in immunology · 2019Article
- Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.Frontiers in immunology · 2019Review
Corrections and comments
- Retraction · 2019-02-20Concerns/Issues about Data · Concerns/Issues about Image · Concerns/Issues about Results and/or Conclusions · Investigation by Journal/Publisher · Upgrade/Update of Prior Notice(s) · · see also: https://www.medscape.com/viewarticle/909288; see also: https://pubpeer.com/publications/D569C47E7BE09AD9D238BA526E06CA
- Expression of concern · 2018-10-25Concerns/Issues about Data · Investigation by Journal/Publisher · Updated to Retraction · · see also: https://www.medscape.com/viewarticle/909288
- Commented on by
- Commented on by
- Commented on by
- Retracted
Authors and funding
27 authors at 10 institutions in 3 countries.
Funding
Abstract
Successful T cell immunotherapy for brain cancer requires that the T cells can access tumour tissues, but this has been difficult to achieve. Here we show that, in contrast to inflammatory brain diseases such as multiple sclerosis, where endothelial cells upregulate ICAM1 and VCAM1 to guide the extravasation of pro-inflammatory cells, cancer endothelium downregulates these molecules to evade immune recognition. By contrast, we found that cancer endothelium upregulates activated leukocyte cell adhesion molecule (ALCAM), which allowed us to overcome this immune-evasion mechanism by creating an ALCAM-restricted homing system (HS). We re-engineered the natural ligand of ALCAM, CD6, in a manner that triggers initial anchorage of T cells to ALCAM and conditionally mediates a secondary wave of adhesion by sensitizing T cells to low-level ICAM1 on the cancer endothelium, thereby creating the adhesion forces necessary to capture T cells from the bloodstream. Cytotoxic HS T cells robustly infiltrated brain cancers after intravenous injection and exhibited potent antitumour activity. We have therefore developed a molecule that targets the delivery of T cells to brain cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.